The treatment of hepatitis B patients should not aim at a complete cure, which is difficult to achieve and may lead to the indiscriminate use of medication, the treatment of hepatitis B should follow the following guidelines and goals: (1) Prevent recurrent activity of the disease Hepatitis B is relatively stable, but in the case of physical decline due to exertion, mental stress or other diseases, there is an increase in ALT and an increase in self-conscious symptoms, which is a sign of relapse. At this time, the vicious cycle of hepatocyte degeneration, necrosis, regeneration and fibrosis leads to further aggravation of liver lesions. The main goal of clinical treatment is to stabilize the disease and prevent its recurrent activity from transforming into an unfavorable one. (2) Inhibition of HBV replication HBV replication is the initiating factor for recurrent and incurable chronic hepatitis B disease. Therefore, clinicians should consider antiviral therapy as a major goal. The specific indicators are negative HBV-DNA, negative HBeAg and positive anti-HBe. -It is generally believed that a negative HBV-DNA transfer is proof that HBV has stopped replicating, there is no source of virus transmission in human circulating blood and body fluids, the patient is not infectious, and the disease will be in a stable state. A small number of anti-HBe positive chronic hepatitis B, HBV-DNA turned negative, but liver function tests ALT or AST is still not normal, may be the continued existence of autoimmune reaction. (3) Improve the microcirculatory blood supply environment of hepatocytes According to electron microscopic observation studies, it is confirmed that most of the inflammation within the liver lobules occurs in the cell bands with inadequate blood supply. Clinical practice also proves that light hepatitis can be relieved by bed rest alone. This indicates that the peripheral blood supply decreases and the visceral blood supply is relatively adequate after the body rests, and the hepatocytes begin to repair and inflammation subsides with an adequate blood supply. Clinicians should make the appropriate application of vasoactive substances to improve the microcirculatory blood supply status of hepatocytes a goal in the treatment of chronic hepatitis B. (4) Reduce liver fibrosis Liver fibrosis is a pre-cirrhotic lesion, and only by effectively controlling the process of liver fibrosis can the occurrence of cirrhosis be prevented. Therefore, reducing or even blocking liver fibrosis is an important indicator of the chronic hepatitis stage. At present, the main drugs for the treatment of liver fibrosis are proprietary Chinese medicine preparations, such as rhubarb sting worm pill, compound turtle shell soft liver tablets, salvia preparations, etc. Interferon also has a certain anti-fibrotic effect. Antiviral drugs such as lamivudine can play an indirect role in reducing liver fibrosis by inhibiting HBV replication and reducing liver inflammation. (5) Prevention of hepatocellular carcinoma In the stage of chronic hepatitis B, the persistent infection of HBV can induce hepatocellular carcinoma, especially the integration of the formation of the HBV genome (clinical mostly “small triplet”) is easy to promote hepatocellular carcinoma. It is generally advocated to actively start antiviral therapy during the inflammatory phase of chronic hepatitis B, so as to play a therapeutic role before HBV integration, because the currently applied antiviral drugs are ineffective against the integrated HBV. Prevention of hepatocellular carcinoma can be considered by applying immune enhancers at the appropriate time, or using Chinese medicinal preparations that invigorate blood circulation and disperse blood stasis, strengthen the spleen and benefit the qi. Since the mechanism of hepatocellular carcinoma is very complicated, even timely application of antiviral drugs may not be able to fundamentally eliminate the occurrence of hepatocellular carcinoma. Therefore, we can only try to reduce the incidence of hepatocellular carcinoma from the perspective of prevention. For the treatment of chronic hepatitis, we should adhere to the viewpoint of combining Chinese and Western medicine with regular treatment and long-term medication. Even if effective, it takes about 1.5 years to replace all HBV-infected hepatocytes with new hepatocytes. Of course, through liver protection and antiviral treatment, most patients can see the effect in about 15 days, liver function significantly improved, about l a 2 months liver function normal, clinical cure. However, the disease can only be stabilized by continuing treatment until HBV-DNA turns negative. The clearance of HBV in the body is the best efficacy for complete cure, and some patients are able to achieve this goal by maintaining treatment for a long time with combined antiviral.